What is Tirzepatide?
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It's the first dual incretin receptor agonist, offering enhanced weight loss and metabolic benefits beyond single-target therapies.
Key Benefits
💪 Superior Weight Loss
Greater weight loss than GLP-1 agonists alone (20-25% reduction)
🎯 Dual Mechanism
Activates both GIP and GLP-1 receptors for synergistic effects
🩸 Glycemic Control
Exceptional blood sugar control for diabetics
🍔 Appetite Suppression
Powerful reduction in appetite and food intake
💊 Metabolic Health
Improves multiple metabolic markers
🧪 Insulin Sensitivity
Enhances insulin function and glucose utilization
How It Works
Tirzepatide's dual action on GIP and GLP-1 receptors creates synergistic effects on appetite, insulin secretion, and fat metabolism. The GIP component may enhance fat burning and reduce inflammation beyond GLP-1 alone.
Typical Dosing Protocol
Dose: Start 2.5 mg weekly, titrate to 5-15 mg weekly
Administration: Subcutaneous injection once weekly
Duration: Long-term weight management protocol
Research Support
Clinical trials show Tirzepatide produces 20-25% weight loss on average, exceeding results from GLP-1 agonists. Studies demonstrate excellent tolerability and sustained weight loss with continued use.